The importance of addressing age-associated cognitive impairment cannot be overstated. The rising prevalence of cognitive impairment such as mild cognitive impairment (MCI) and dementia, including Alzheimer disease, is becoming a worldwide concern.1 In this issue of JAMA, the US Preventive Services Task Force (USPSTF) concludes that “the current evidence is insufficient to assess the balance of benefits and harms of screening for cognitive impairment in older adults (I statement).”2 This recommendation is based on an evidence report and systematic review of the literature that assessed the accuracy of cognitive screening instruments and the benefits and harms of interventions to treat cognitive impairment.3 That report represents an update of the previous report on this topic published in 2014.4
Petersen RC, Yaffe K. Issues and Questions Surrounding Screening for Cognitive Impairment in Older Patients. JAMA. 2020;323(8):722–724. doi:10.1001/jama.2019.22527
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: